IP Library Granted Patent US 11,085,047
Granted Patent B2
US 11,085,047 · App. 16/612,472 · Granted Aug 10, 2021

Synthetic cannabinoid compounds for treatment of substance addiction and other disorders

Inventor: Jonnie R. Williams (Sarasota, FL)
Assignee: MyMD Pharmaceuticals (Florida), Inc.
C12N15/8243A61K31/352A61K36/185C12N15/8257
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,085,047
App. No.
16/612,472
Granted
Aug 10, 2021
Kind
B2
Abstract

A method of increasing the cannabinoid levels in a genetically modified Cannabis sativa plant includes genetically modifying the plant to induce the overexpression of the gene that controls the expression of tetrahydrocannabinolic acid (THCA) synthase and/or cannabidiolic acid (CBDA) synthase. The overexpression of THCA synthase and CBDA synthase catalyzes an increased synthesis of cannabigerolic acid to tetrahydrocannabinolic acid and cannabidiolic acid, as well as the cannabinoids (3aR)-2,4,4-trimethyl-7-pentyl-3,3a,4,9b-tetrahydrocyclopenta[c]chromen-9-ol and 2-((1R,5R)-3-methyl-5-(prop-1-en-2-yl)cyclopent-2-en-1-yl)-5-pentylbenzene-1,3-diol. Pharmaceutical compositions comprising the modified cannabinoids produced by the transgenic Cannabis sativa plant or prepared synthetically are used to treat various diseases and conditions.

Claims (9)

1. A compound having the structure:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of claim 1 having the structure:

or a pharmaceutically acceptable salt thereof, and

a pharmaceutically acceptable vehicle therefor.

3. A pharmaceutical composition of claim 2 which contains a racemic mixture of enantiomers having the structures:

4. A pharmaceutical composition of claim 3 , wherein the pharmaceutically acceptable vehicle is a capsule, tablet, syrup, lozenge, inhaler, e-cigarette, chewable gum, nasal spray, transdermal patch, liquid, transmucosal vehicle, hydrogel, nanosome, liposome, noisome, nanoparticle, nanosphere, microsphere, microparticle, microemulsion, nanosuspension, or micelle.

5. A pharmaceutical composition of claim 2 which contains an enantiomer, of at least about 99% enantiomeric purity, having the structure:

6. A pharmaceutical composition of claim 5 , wherein the pharmaceutically acceptable vehicle is a capsule, tablet, syrup, lozenge, inhaler, e-cigarette, chewable gum, nasal spray, transdermal patch, liquid, transmucosal vehicle, hydrogel, nanosome, liposome, noisome, nanoparticle, nanosphere, microsphere, microparticle, microemulsion, nanosuspension, or micelle.

Assignments (5)
CHANGE OF NAME Recorded Jun 10, 2025
From: MYMD PHARMACEUTICALS, INC.
To: TNF PHARMACEUTICALS, INC.
Reel/Frame 071501/0834 →
MERGER Recorded Apr 22, 2022
From: MYMD PHARMACEUTICALS (FLORIDA), INC.
To: MYMD PHARMACEUTICALS, INC.
Reel/Frame 059680/0941 →
CHANGE OF NAME Recorded Jun 28, 2021
From: MYMD PHARMACEUTICALS, INC.
To: MYMD PHARMACEUTICALS (FLORIDA), INC.
Reel/Frame 056689/0108 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2021
From: SUPERA PHARMACEUTICALS, INC.
To: MYMD PHARMACEUTICALS, INC.
Reel/Frame 056675/0839 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2019
From: WILLIAMS, JONNIE R.
To: SUPERA PHARMACEUTICALS, INC.
Reel/Frame 051214/0238 →
Continuity (2)
Provisional Application 62632448 · Feb 20, 2018
Related Publication 20200061138A1 · Feb 27, 2020